QUEBEC CITY, April 20 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that preclinical data in neuroblastoma for perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, will be presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR), currently being held at the Walter E. Washington Convention Center in Washington, DC.
The following poster will be presented in Exhibit Hall A-C on Wednesday, April 21, 2010, from 8:00am-11:00am:
Abstract # 5248
Presentation "Neuroblastoma tumors with different ALK mutations
Title: are sensitive to Perifosine"
Poster Section: 16
Poster Board Number: 2
Author Block: Zhijie Li, Carol J. Thiele
Cell & Molecular Biology Section
POB/NCI/NIH, Bethesda, MD
Data demonstrating that single agent perifosine targets activation of Akt in neuroblastoma cells and xenografts, significantly inhibited tumor growth in vivo and improved the survival of mice bearing neuroblastoma tumors, was originally presented at the 2009 AACR annual meeting by the same group from the Pediatric Oncology Branch of the National Institute of Health.
A Phase 1 trial exploring the safety and efficacy of single agent perifosine in patients with pediatric tumors, including neuroblastoma, is currently being conducted by Memorial Sloan Kettering Cancer Center.
A copy of the above abstract is currently available and can be viewed on-line through the AACR 2010 Meeting website at: http://www.aacr.org/home/scientists/meetings--workshops/aacr-101st-annual-meeting-2010/abstracts.aspx.
Perifosine is currently in Phase 3 clinical development for refractory advanced colorectal cancer and multiple myeloma, both of these Phase 3 programs being conducted under Special Protocol Assessment (SPA) agreements with the FDA, and in Phase 1 and 2 clinical development for several other tumor types. Keryx Biopharmaceuticals Inc. (Nasdaq: KERX) Aeterna Zentaris' partner and licensee for perifosine in the United States, Canada and Mexico. Aeterna Zentaris has also out-licensed perifosine to Handok in South Korea while retaining rights for the rest of the world.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.
SOURCE Aeterna Zentaris Inc.
For further information: For further information: Investor Relations: Ginette Vallières, Investor Relations Coordinator, (418) 652-8525, ext. 265, email@example.com; Media Relations: Paul Burroughs, Director of Communications, (418) 652-8525, ext. 406, firstname.lastname@example.org